Woo, T.E.; Stukalin, I.; Ding, P.Q.; Goutam, S.; Sander, M.; Ewanchuk, B.; Cheung, W.Y.; Heng, D.Y.C.; Cheng, T.
Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma. Curr. Oncol. 2023, 30, 8936-8947.
https://doi.org/10.3390/curroncol30100646
AMA Style
Woo TE, Stukalin I, Ding PQ, Goutam S, Sander M, Ewanchuk B, Cheung WY, Heng DYC, Cheng T.
Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma. Current Oncology. 2023; 30(10):8936-8947.
https://doi.org/10.3390/curroncol30100646
Chicago/Turabian Style
Woo, Taylor E., Igor Stukalin, Philip Q. Ding, Siddhartha Goutam, Michael Sander, Benjamin Ewanchuk, Winson Y. Cheung, Daniel Y. C. Heng, and Tina Cheng.
2023. "Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma" Current Oncology 30, no. 10: 8936-8947.
https://doi.org/10.3390/curroncol30100646
APA Style
Woo, T. E., Stukalin, I., Ding, P. Q., Goutam, S., Sander, M., Ewanchuk, B., Cheung, W. Y., Heng, D. Y. C., & Cheng, T.
(2023). Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma. Current Oncology, 30(10), 8936-8947.
https://doi.org/10.3390/curroncol30100646
